奥比他韦/帕利瑞韦/利托那韦联合达萨布韦±利巴韦林在肾病患者中的疗效与安全性
该事后汇总分析纳入11项3期临床试验中HCV基因1型感染合并CKD 1–3期且肝功能代偿的患者,评估含或不含利巴韦林的全口服直接抗病毒方案。各CKD分期的SVR12率均较高,严重不良事件和肾脏相关不良事件发生率低,方案总体耐受良好。
要点
- 含或不含利巴韦林方案在CKD 1–3期患者中SVR12率达93%–98%。
- 严重不良事件和肾脏相关不良事件总体发生率分别为3%和2%。
- 基线蛋白尿、BMI、非黑人种族和糖尿病史与eGFR提升≥10相关。
核心结论
- OBV/PTV/r + DSV ± RBV在不同CKD分期患者中均获得高SVR率且总体耐受良好。
研究设计与样本
- 事后汇总分析纳入11项3期临床试验中HCV基因1型感染、肝功能代偿且CKD 1–3期的患者。
- 治疗方案为全口服OBV/PTV/r + DSV ± RBV。
主要发现
- OBV/PTV/r + DSV组CKD 1、2、3期SVR12率分别为97%(439/453)、98%(536/547)、97%(32/33)。
- OBV/PTV/r + DSV + RBV组CKD 1、2、3期SVR12率分别为96%(1172/1221)、96%(1208/1254)、93%(55/59)。
- 总体严重不良事件发生率为3%(95/3567),肾脏相关不良事件为2%(56/3567)。
- 与eGFR提升≥10 ml/min per 1.73 m2相关的因素包括基线蛋白尿、BMI、非黑人种族和糖尿病史。
临床怎么用
- 对于HCV基因1型感染合并CKD 1–3期且肝功能代偿的患者,可考虑使用OBV/PTV/r + DSV ± RBV方案。
- 治疗期间需关注严重不良事件和肾脏相关不良事件,总体发生率较低。
局限性
- 为事后汇总分析,非预设主要终点。
- 仅纳入CKD 1–3期且肝功能代偿的患者,未涵盖CKD 4–5期或透析人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. METHODS: We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1-infected patients with compensated liver disease and CKD stages 1 to 3 who received the all-oral 3-direct-acting antiviral regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir ± ribavirin (OBV/PTV/r + DSV ± RBV) in 11 phase 3 clinical trials. Sustained virologic response rates at posttreatment week 12 (SVR12) and treatment-related adverse events (AEs), serious AEs, and renal-associated AEs are reported. Mean changes from baseline in serum creatinine and estimated glomerular filtration rate (eGFR) were calculated to assess changes in renal function. Factors associated with improved eGFR were assessed by stepwise logistic regression analysis of data from 7 trials in which baseline urinalysis was collected. RESULTS: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m2 were baseline proteinuria, body mass index, nonblack race, and history of diabetes. CONCLUSION: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.
引用
- Bernstein DE, Tran A, Martin P, et al. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep. 2018. PMID: 30775621. doi:10.1016/j.ekir.2018.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。